Alpha memo: resveratrol exercise animal-disease-to-aged-men endpoint boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rename or restructure to match the actual evidence: either (a) reframe as 'combined resveratrol+exercise protocol in AD-mice vs exercise-alone in healthy aged-men — a cross-species, cross-endpoint, cross-health-status boundary,' explicitly noting that Receipt 1 does not isolate resveratrol's single-agent contribution, or (b) drop the combined-protocol framing and re-anchor on what Receipt 1 and Receipt 2 actually share (resveratrol + exercise) and what they do not (single-agent resveratrol isolation in animal disease; skeletal-muscle metabolic/inflammatory endpoints).
2. Clarify in the alpha that Receipt 1's 'combined protocol' cannot be decomposed into resveratrol-alone vs exercise-alone contributions, so any 'boundary' claim must explicitly state it is between a combined-intervention animal-disease study and a component-resolved human-healthy study, not between matched single-agent interventions.
3. Add Receipt 2's key parameters (250 mg/day, 8 weeks, men 60-72, healthy/inactive) to the synthesis so the falsifier is concrete and the boundary's scope is unambiguous.
4. State the health-status contrast (3xTg AD mice vs healthy aged men) as a co-equal boundary axis alongside species, modality, and endpoint.

Major issues

• Title/anchor mismatch: the title says 'resveratrol exercise animal-disease-to-aged-men endpoint boundary' and the one-sentence alpha frames this as a 'combined-protocol cardiac/aortic signal' in mice versus 'skeletal/metabolic in aged-men.' However, Receipt 1 tests a combined resveratrol+exercise protocol and does not isolate components; Receipt 2 explicitly isolates exercise from resveratrol (the title states 'but not resveratrol'). The memo cannot make a clean boundary claim about a 'combined-protocol signal' transferring because Receipt 1 never isolates that protocol from its single components. The receipt-role check claims Receipt 1 is 'treated as the full combined protocol named in its title' but the memo simultaneously wants to 'separate the components,' which Receipt 1 does not do. This is internally contradictory.
• The surprise/alpha conflates two different compound-specific questions: (a) does combined resveratrol+exercise work in animal-disease vs human-healthy? and (b) does resveratrol-alone work in aged-men skeletal muscle? These are distinct hypotheses bolted together as one 'endpoint boundary' update without clearly stating that Receipt 1 cannot adjudicate resveratrol's standalone contribution.
• Title uses 'alpha' as a noun in a way that may be read as a generalized resveratrol efficacy claim rather than a bounded boundary signal; readers could misread this as 'resveratrol works in mice but not humans.'

Minor issues

• The 'Why this is surprising' section restates the boundary without adding mechanistic or evidentiary explanation of what specifically is being updated beyond 'species and endpoint differ.'
• Receipt 1 excerpt is truncated mid-sentence at 'Late (A) ventricular filling ve' which slightly weakens grounding, though the DOI and title are clear.
• The memo does not report dose, duration, or sample characteristics from Receipt 2 (250 mg/day resveratrol, 8 weeks, men 60-72) which are directly relevant to the falsifier design.
• No mention of the healthy-vs-disease status distinction is foregrounded in the alpha, even though Receipt 2 explicitly studies healthy aged men.

Reviewer note

The memo identifies a legitimate boundary between two real and well-matched receipts (3xTg AD-mice cardiovascular study with combined resveratrol+exercise, 2014; aged-men skeletal-muscle study with isolated resveratrol and exercise arms, 2014 — but actually 2014 is Receipt 2, 2019 is Receipt 1, which is correct). The limitation and falsifier sections are competent and the source bundle is accurate. However, the central 'combined-protocol signal' framing is not honest about what Receipt 1 can and cannot say: Receipt 1 tests resveratrol+exercise together and does not separate them, so the memo cannot claim the boundary is about 'combined protocol transfer' vs 'isolated resveratrol failure' — those are different boundaries. The title and alpha need to be rewritten to match the actual evidence structure, after which this becomes a clean accept. Recommend revise with bounded title/alpha rewrite.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis